Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Acute uterine bleeding unrelated to pregnancy.

BIBLIOGRAPHIC SOURCE(S)

  • Kaiser Permanente Southern California. Acute uterine bleeding unrelated to pregnancy. Pasadena (CA): Kaiser Permanente Southern California; 2006 Aug. 27 p. [70 references]

GUIDELINE STATUS

This is the current release of the guideline.

BRIEF SUMMARY CONTENT

 
RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

Hierarchy (classes) of evidence (1– 6) and support for recommendation (A –D and I) definitions are given at the end of the "Major Recommendations" field.

Summary of Recommendations

Recommendations are evidence based (E) unless sufficient evidence is not available where consensus-based recommendations are provided (C).

  Method* Strength** Recommendation
1 C N/A It is important to exclude pregnancy in all patients with acute abnormal uterine bleeding (AUB) in the reproductive years.
2 E A Perimenarcheal patients with acute AUB may be at increased risk for an inherited coagulopathy and should be screened accordingly with a structured history. (See Appendix III in the original guideline document).
3 C N/A Hemodynamically stable patients may be offered either oral multidose progestins, or oral multidose, monophasic, combination oral contraceptives. (See Appendix IV in the original guideline document).
4 E C There is fair evidence supporting the efficacy of intravenous conjugated equine estrogens for hemodynamically-stable patients.
5 C N/A Dilation and curettage (D&C) should be reserved for patients who, in the opinion of the clinician, are inappropriate for, unresponsive to, or contraindicated from the use of medical therapy.
6 E A When performed, D&C should be accompanied by hysteroscopy.
7 C N/A Parenteral antifibrinolytic agents such as epsilon aminocaproic acid may have a role in the management of patients with recalcitrant acute AUB who otherwise would be candidates for more invasive surgical procedures including those that remove fertility, such as hysterectomy.
8 C N/A Patients with acute uterine bleeding may be offered surgical alternatives to D&C that may preserve fertility including intrauterine Foley balloon and uterine artery occlusion/embolization.
9 C N/A In some instances it will be necessary to offer patients options that will remove future fertility by removing or destroying the endometrium. These include endometrial ablation and hysterectomy.
10 E A Many patients with acute uterine bleeding have an underlying chronic disorder that requires systematic evaluation and, in many instances, chronic therapy, following the arrest of the acute phase of the process.

*E = Evidence-based; C = Consensus-based

**See Definitions below; Strength of evidence is not applicable (N/A) to consensus-based recommendations.

Definitions:

Hierarchy of Evidence*

  1. Randomized controlled trials
  2. Non-randomized, but internally controlled trials. Controls are considered to be "internal" if they are included in the original design of the study.  Post hoc or historical comparisons are not considered internal controls. Comparisons of otherwise uncontrolled clinical series are not considered internal controls
  3. Case control studies
  4. Cohort studies
  5. Clinical series, without internal comparison
  6. Expert opinion, without available clinical studies**

Support for Recommendations*

Recommendation: A

Language: The Guideline Development Team (GDT) strongly recommends that clinicians routinely provide the intervention to eligible patients.

Evidence: The intervention improves important health outcomes, based on good evidence, and the GDT concludes that benefits substantially outweigh harms and costs.

Recommendation: B

Language: The GDT recommends that clinicians routinely provide the intervention to eligible patients.

Evidence: The intervention improves important health outcomes, based on 1) good evidence that benefits outweigh harms and costs; or 2) fair evidence that benefits substantially outweigh harms and costs.

Recommendation: C

Language: The GDT makes no recommendation for or against routine provision of the intervention. At the discretion of the GDT, the recommendation may use the language "option," but must list all the equivalent options.

Evidence: Evidence is sufficient to determine the benefits, harms, and costs of an intervention, and there is at least fair evidence that the intervention improves important health outcomes. But the GDT concludes that the balance of the benefits, harms, and costs is too close to justify a general recommendation.

Recommendation: D

Language: The GDT recommends against routinely providing the intervention to eligible patients.

Evidence: The GDT found at least fair evidence that the intervention is ineffective, or that harms or costs outweigh benefits.

Recommendation: I

Language: The GDT concludes that the evidence is insufficient to recommend for or against routinely providing the intervention. At the discretion of the GDT, the recommendation may use the language "option," but must list all the equivalent options.

Evidence: Evidence that the intervention is effective is lacking, of poor quality, or conflicting and the balance of benefits, harms, and costs cannot be determined.

*Kaiser Permanente National Guideline Directors Group, Edition 3, September 1, 2004

**Level of evidence added by the Abnormal Uterine Bleeding Work Group (AUBWG).

CLINICAL ALGORITHM(S)

A clinical algorithm is provided in the original guideline document for acute uterine bleeding.

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is identified and graded for each recommendation (see "Major Recommendations").

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • Kaiser Permanente Southern California. Acute uterine bleeding unrelated to pregnancy. Pasadena (CA): Kaiser Permanente Southern California; 2006 Aug. 27 p. [70 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2006 Aug

GUIDELINE DEVELOPER(S)

Kaiser Permanente-Southern California - Managed Care Organization

SOURCE(S) OF FUNDING

Kaiser Permanente Southern California

GUIDELINE COMMITTEE

Southern California Permanente Medical Group, Abnormal Uterine Bleeding Working Group

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Clinical Lead: Malcolm Munro, MD (Chair)

Kaiser Permanente Southern California Abnormal Uterine Bleeding Working Group Members: Michael Amann, MD; Hector Anguiano, MD; Rosalie Bauman, MD; Mon-Lai Chung, MD; Selena Harris, MD; Murali Kamath, MD; John Kennedy, MD; Seth Kivnick, MD; Aaron Lim, MD; Malcolm Munro, MD (Chair); Saad Solh, MD

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

GUIDELINE AVAILABILITY

Electronic copies: Available from Marguerite Koster, Practice Leader, Technology Assessment and Guidelines Unit, Kaiser Permanente Southern California; Email: Marguerite.A.Koster@kp.org

Print copies: Available from Malcolm G. Munro, MD, FRCS(c), FACOG, Department of Obstetrics and Gynecology, Kaiser Permanente Southern California, Professor, Department of Obstetrics & Gynecology, David Geffen School of Medicine at UCLA; Email: M.G.Munro@kp.org

AVAILABILITY OF COMPANION DOCUMENTS

None available

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI on September, 20, 2006. The information was verified by the guideline developer on December 6, 2006.

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to Kaiser Permanente Southern California's copyright restrictions.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo